Zydus Gets EIR For Ahmedabad Injectables Manufacturing Facility
The inspection was conducted by the top US regulatory authority from 5th to 13th June 2023, the inspection was a cGMP inspection and had ended with NIL observations
Zydus Lifesciences on Wednesday said that it has received the establishment inspection report (EIR) from the United States Food and Drugs Administration (USFDA) for the inspection conducted at the injectables manufacturing facility at Zydus Biotech Park located at Changodar, Ahmedabad
The inspection was conducted by the top US regulatory authority from 5th to 13th June 2023, the inspection was a cGMP inspection and had ended with NIL observations.
The company's stock closed 2.47 per cent higher at Rs 643.15 per scrip on BSE.
